GPRIN1 Antibody

What is GPRIN1 and what cellular functions does it regulate?

GPRIN1 is a membrane-bound protein that functions as a downstream effector for Gα o/i/z proteins in neurons. It is highly localized to the plasma membrane and synapses where it regulates neuronal signal transduction and calcium homeostasis . GPRIN1 plays a crucial role in neurite outgrowth and is enriched in the growth cones of developing neurites .

The protein is strongly expressed throughout the adult mouse brain, with particular enrichment in the hippocampus, hypothalamus, habenula, and cerebral cortex . Functionally, GPRIN1 contributes to both early neuronal network development and mature neuronal function, affecting calcium signaling after agonist-induced physiological responses and contributing to spontaneous neuronal electrical activity .

What types of GPRIN1 antibodies are available for research applications?

Multiple types of GPRIN1 antibodies are available from various suppliers, including:

• Polyclonal antibodies: Developed in rabbit, these recognize various epitopes on the GPRIN1 protein and are suitable for applications like Western blotting, ELISA, and immunohistochemistry

• Monoclonal antibodies: More specific than polyclonal antibodies, these are available in mouse (e.g., Clone ID: K1G4) and are particularly useful for immunohistochemistry applications

• Region-specific antibodies: Targeted against specific regions of GPRIN1, such as C-terminal or N-terminal domains

• Conjugated antibodies: Available with various tags including biotin, FITC, HRP, and Alexa fluorophores for specialized applications

Most commercially available antibodies exhibit reactivity with human GPRIN1, while some also cross-react with mouse and rat orthologs due to sequence homology .

What are the validated applications for GPRIN1 antibodies?

GPRIN1 antibodies have been validated for numerous research applications, as evidenced by supplier data and research publications:

Most antibodies show endogenous-level sensitivity and can detect the native protein without overexpression systems .

How should I optimize Western blotting protocols for GPRIN1 detection?

When detecting GPRIN1 via Western blotting, consider these methodological recommendations:

• Sample preparation: For neuronal samples, use RIPA buffer supplemented with protease inhibitors to prevent degradation of GPRIN1 during extraction .

• Gel selection: Since GPRIN1 has a molecular weight of approximately 135 kDa, use 8-10% SDS-PAGE gels for optimal resolution .

• Transfer conditions: Employ wet transfer at 30V overnight at 4°C for efficient transfer of high molecular weight GPRIN1 protein.

• Blocking: Block membranes with 5% non-fat milk in TBST for 1 hour at room temperature to minimize background.

• Primary antibody incubation: Dilute GPRIN1 antibody 1:1000 in blocking buffer and incubate overnight at 4°C for optimal signal-to-noise ratio .

• Controls: Include positive controls (brain tissue lysate) and negative controls (tissues known to have low GPRIN1 expression) to validate specificity.

• Signal detection: For low abundance samples, consider using enhanced chemiluminescence substrates with longer exposure times.

To troubleshoot common issues, ensure fresh samples, optimize antibody concentration, and validate antibody specificity using GPRIN1 knockout samples when available .

What are the recommended protocols for immunohistochemistry with GPRIN1 antibodies?

For successful immunohistochemical detection of GPRIN1 in tissue sections:

• Tissue fixation: Use 4% paraformaldehyde (PFA) fixation for optimal antigen preservation. For paraffin-embedded tissue, perform heat-mediated antigen retrieval using citrate buffer (pH 6.0) .

• Section thickness: Use 5-10 μm sections for optimal antibody penetration and signal resolution.

• Blocking: Block with 10% normal serum (from the species of secondary antibody) with 0.3% Triton X-100 in PBS for 1-2 hours.

• Primary antibody dilution: Start with a 1:2500 dilution for paraffin sections as demonstrated for human caudate tissue . Optimize as needed.

• Incubation conditions: Incubate primary antibody at 4°C overnight for best results.

• Detection system: Use biotin-streptavidin amplification or polymer-based detection systems for heightened sensitivity.

• Counterstaining: Nuclear counterstain with hematoxylin provides valuable context for cellular localization.

For dual labeling experiments, GPRIN1 antibodies can be combined with markers for specific neuronal populations to assess colocalization patterns in regions of interest such as hippocampus and cerebral cortex .

How can I use GPRIN1 antibodies for live-cell imaging studies?

For dynamic studies of GPRIN1 localization and function in live neurons:

• Expression system selection: For live imaging of GPRIN1, adenoviral vectors expressing GPRIN1-GFP fusion proteins have been successfully used in primary neuronal cultures .

• Infection protocol:

  • Seed primary neurons on poly-L-ornithine (PLO) coated coverslips

  • Infect neurons with GPRIN1-GFP adenoviral vector after 3 days in vitro (DIV)

  • Allow 48 hours post-infection for protein expression

• Complementary staining: Combine with Sir-Actin (Spirochrome) to visualize cytoskeletal dynamics in relation to GPRIN1 localization .

• Imaging parameters: Use confocal microscopy with appropriate environmental controls (37°C, 5% CO2) to maintain neuronal viability during extended imaging sessions.

• Stimulation experiments: For functional studies, KCl (30 mM) can be used to depolarize neurons and observe GPRIN1 dynamics during neuronal activation .

This approach allows for real-time visualization of GPRIN1 trafficking and its relationship to cytoskeletal rearrangements during neurite outgrowth or in response to stimulation.

How does GPRIN1 interaction with G-protein coupled receptors influence neuronal signaling?

GPRIN1 serves as a critical modulator of G-protein coupled receptor (GPCR) signaling cascades through several key mechanisms:

• G-protein interaction specificity: GPRIN1 shows preferential interaction with activated Gα o/i/z proteins, serving as a downstream effector that translates G-protein activation into cellular responses .

• Nicotinic acetylcholine pathway modulation: GPRIN1 interacts with β2 subunits of nicotinic acetylcholine receptors (nAChRs) and other nAChR-interacting proteins, including G protein α and G protein-activated K+ channel 1 . This interaction facilitates the activation of nicotinic acetylcholine pathways critical for neuronal function.

• Serotonergic signaling enhancement: GPRIN1 interacts with the serotonin receptor 5-HT6R, potentiating its constitutive activation of Gs-coupled receptor pathways. This interaction promotes neurite elongation and branching specifically in striatal neurons .

• Phosphorylation-dependent regulation: CDK5 interacts with the 5-HT6R C-terminal domain and phosphorylates it at Ser350, which increases the binding affinity of GPRIN1 to the receptor .

To study these interactions experimentally, researchers can use co-immunoprecipitation assays with GPRIN1 antibodies, proximity ligation assays, or FRET-based approaches to visualize protein-protein interactions in living neurons.

What insights have GPRIN1 knockout models provided about neuronal function?

GPRIN1 knockout models have revealed several critical functions of this protein in neuronal physiology:

• Learning and memory deficits: GPRIN1 whole-body knockout mice show learning deficits in vivo, demonstrating the protein's importance in cognitive function .

• Neuronal stress sensitivity: Loss of GPRIN1 sensitizes neurons to stress conditions, suggesting a neuroprotective role for this protein .

• Calcium homeostasis disruption: GPRIN1-deficient neurons show altered calcium signaling after agonist-induced physiological responses, indicating its importance in maintaining calcium homeostasis .

• Impacts on spontaneous neuronal activity: GPRIN1 contributes to spontaneous neuronal electrical activity, with knockout neurons showing altered electrophysiological profiles .

• Developmental and mature neuron effects: GPRIN1 plays distinct roles in both early neuronal network development and in functionally mature neurons .

For researchers interested in studying GPRIN1 function, knockout models provide valuable tools for understanding its physiological roles, though careful consideration of developmental compensation mechanisms is essential for data interpretation.

What techniques are recommended for studying GPRIN1's role in cytoskeletal reorganization?

To investigate GPRIN1's role in regulating neuronal cytoskeletal dynamics:

• Live imaging approaches:

  • Combine GPRIN1-GFP with actin visualization tools like Sir-Actin

  • Use adenoviral vectors for expression in primary neurons

  • Perform time-lapse imaging to track cytoskeletal reorganization

• Pharmacological manipulations:

  • Compare cytoskeletal dynamics before and after treatment with receptor agonists

  • Use KCl (30 mM) to depolarize neurons and trigger activity-dependent reorganization

  • H2O2 (200 μM) treatment can be used to induce stress conditions

• Knockdown/knockout approaches:

  • shRNA targeting GPRIN1 in neuroblastoma cell lines like SH-SY5Y

  • CRISPR-Cas9 mediated knockout in primary neurons

  • Comparison with GPRIN1-overexpressing neurons to determine dose-dependent effects

• Neurite outgrowth assays:

  • Quantify neurite length, branching complexity, and growth cone morphology

  • Assess cytoskeletal protein distribution (actin, tubulin) using immunofluorescence

  • Measure the effect of GPRIN1 manipulation on neurite outgrowth dynamics

These methodological approaches enable researchers to dissect GPRIN1's specific contributions to the complex process of cytoskeletal reorganization during neuronal development and in response to physiological stimulation.

Why might I observe inconsistent results with GPRIN1 antibodies and how can I improve specificity?

Inconsistencies in GPRIN1 antibody performance can stem from several factors:

• Epitope accessibility issues: GPRIN1's membrane localization and interaction with multiple binding partners may mask epitopes, resulting in variable detection efficiency. Solution: Try antibodies targeting different regions (N-terminal versus C-terminal) .

• Post-translational modifications: GPRIN1 undergoes phosphorylation and possibly other modifications that might affect antibody recognition. Solution: Consider using phospho-specific antibodies when studying signaling dynamics .

• Tissue-specific expression variations: GPRIN1 shows differential expression across brain regions, with enrichment in hippocampus, hypothalamus, habenula, and cerebral cortex . Solution: Use appropriate positive control tissues from these regions.

• Fixation-dependent epitope sensitivity: Some epitopes may be sensitive to specific fixation methods. Solution: Compare performance with different fixation protocols (e.g., PFA versus methanol) and optimize antigen retrieval methods .

• Cross-reactivity concerns: Some antibodies may cross-react with related proteins. Solution: Validate antibody specificity using GPRIN1 knockout tissues or cells when available .

To systematically improve specificity, implement multiple validation approaches including Western blotting, immunoprecipitation, immunofluorescence pattern analysis, and knockout validation.

What controls should be included when studying GPRIN1 in different experimental systems?

A comprehensive control strategy should include:

• Positive tissue controls:

  • Brain regions with known high GPRIN1 expression (hippocampus, cerebral cortex)

  • Cell lines with validated GPRIN1 expression (e.g., SH-SY5Y neuroblastoma cells)

• Negative controls:

  • GPRIN1 knockout or knockdown samples when available

  • Primary antibody omission controls

  • Isotype controls to assess non-specific binding

• Specificity controls:

  • Pre-absorption of antibody with immunizing peptide

  • Multiple antibodies targeting different GPRIN1 epitopes

  • Western blot validation alongside immunofluorescence to confirm specificity

• Loading/staining controls:

  • Housekeeping proteins (β-actin, GAPDH) for Western blotting

  • Nuclear counterstains (DAPI, Hoechst) for immunofluorescence studies

  • Neuronal markers (MAP2, NeuN) to identify target cell populations

• Experimental manipulation controls:

  • Vehicle-only treatments for stimulation experiments

  • Non-targeting shRNA/siRNA for knockdown studies

  • Empty vector controls for overexpression studies

Documenting these controls systematically improves data reliability and facilitates troubleshooting when unexpected results arise.

How can I distinguish between specific and non-specific signals when using GPRIN1 antibodies?

To differentiate between specific and non-specific signals:

• Expected cellular localization: Authentic GPRIN1 signal should show enrichment at plasma membrane, synapses, and particularly in growth cones of developing neurites . Diffuse cytoplasmic or nuclear staining patterns likely represent non-specific binding.

• Molecular weight verification: In Western blots, GPRIN1 should appear at approximately 135 kDa . Additional bands may indicate degradation products, cross-reactivity, or post-translational modifications.

• Signal reduction tests:

  • Concentration-dependent signal: Specific signal should decrease proportionally with antibody dilution

  • Competition with immunizing peptide should reduce specific signal

  • Signal should be diminished or absent in knockdown/knockout samples

• Comparison across detection methods: Correlation between Western blot, immunofluorescence, and other detection methods increases confidence in specificity.

• Signal correlation with known GPRIN1 expression patterns:

  • Higher signal in hippocampus, hypothalamus, habenula, and cerebral cortex compared to regions with lower expression

  • Developmental regulation pattern consistent with known GPRIN1 ontogeny

By implementing these approaches systematically, researchers can confidently identify authentic GPRIN1 signals and avoid misinterpreting experimental results.

How is GPRIN1 being studied in relation to learning and memory functions?

Recent research has established important connections between GPRIN1 and cognitive processes:

• Learning deficits in knockout models: GPRIN1 knockout mice display learning deficits in behavioral testing, providing direct evidence for GPRIN1's role in cognitive function .

• Neuronal circuit involvement: GPRIN1's enrichment in the hippocampus, a brain region critical for learning and memory formation, suggests its importance in mediating synaptic plasticity underlying memory .

• Synaptic localization: GPRIN1's presence at synapses positions it to influence synaptic transmission and plasticity, the cellular correlates of learning and memory .

• Calcium homeostasis regulation: GPRIN1 regulates neuronal calcium signaling, which is fundamental to synaptic plasticity mechanisms including long-term potentiation (LTP) and long-term depression (LTD) .

• G-protein signaling modulation: Through its interactions with G-protein coupled receptors (particularly cholinergic and serotonergic systems), GPRIN1 likely influences neurotransmitter systems known to be critical for learning and cognitive function .

Future research directions may include more detailed behavioral characterization of GPRIN1-deficient animal models, investigation of region-specific GPRIN1 functions using conditional knockout approaches, and exploration of potential GPRIN1 involvement in cognitive disorders.

What are the latest findings on GPRIN1's role in neuronal stress responses?

Emerging evidence highlights GPRIN1's involvement in neuronal stress responses:

• Stress sensitivity: Loss of GPRIN1 sensitizes neurons to stress conditions, suggesting a neuroprotective function under challenging cellular environments .

• Oxidative stress models: GPRIN1 knockout neurons show altered responses to oxidative stress induced by H2O2 treatment (200 μM), providing experimental models to study its protective mechanisms .

• Calcium homeostasis under stress: GPRIN1 regulates calcium signaling, which can become dysregulated during cellular stress, potentially contributing to excitotoxicity and neuronal damage .

• Cytoskeletal reorganization during stress: GPRIN1's involvement in cytoskeletal dynamics may be particularly important during stress responses, when neurons must adapt their morphology and connectivity .

• Potential therapeutic implications: Understanding GPRIN1's role in stress response might inform neuroprotective strategies for conditions involving neuronal stress, including neurodegenerative diseases and traumatic brain injury.

Research methodologies to explore these aspects include calcium imaging in GPRIN1-deficient neurons exposed to various stressors, assessment of cell viability and morphology after stress induction, and evaluation of stress-response pathway activation through phospho-specific antibodies.

How might GPRIN1 dysregulation contribute to neurological disorders?

While direct evidence linking GPRIN1 dysfunction to specific neurological disorders remains limited, several lines of evidence suggest potential involvement:

• Learning and memory implications: Given the learning deficits observed in GPRIN1 knockout mice , dysregulation might contribute to cognitive disorders.

• Neurodevelopmental considerations: GPRIN1's role in neurite outgrowth and early neuronal network formation suggests potential involvement in neurodevelopmental disorders if its function is compromised .

• Synaptic function: As a regulator of neuronal signal transduction at synapses , GPRIN1 dysfunction could contribute to synaptic pathologies seen across multiple neurological conditions.

• G-protein coupled receptor signaling: GPRIN1 modulates several neurotransmitter systems through GPCR interactions , many of which are targeted by drugs used to treat psychiatric and neurological disorders.

• Stress sensitivity: GPRIN1's role in neuronal stress responses suggests that its dysfunction might exacerbate neurodegeneration in conditions with oxidative stress components.

Future research directions may include genetic association studies in patient populations, more detailed phenotyping of GPRIN1-deficient animal models for disease-relevant behaviors, and investigation of GPRIN1 expression and function in post-mortem brain tissue from individuals with neurological disorders.